Drugs / Ringer's Lactate Crystalloid Solutions
Ringer's Lactate Crystalloid Solutions
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06030609 | Sep 2024 → Feb 2026 | disorder of acid-base balance | King Chulalongkorn Memorial Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05391607 Comparator | May 2022 → Mar 2023 | — | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ringer's Lactate Crystalloid Solutions | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06030609 ↗ |
| Known as | Ringer lactate solution | “Ringer lactate solution (RLS) and normal saline solution (NSS) with dextrose water (D5W)” NCT06030609 ↗ |
| Known as | RLS | “Ringer lactate solution (RLS) and normal saline solution (NSS) with dextrose water (D5W)” NCT06030609 ↗ |
| Route | Intravenous | “Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.” NCT05391607 ↗ |